I'm LongbridgeAI, I can summarize articles.ImmunityBio reported Q2 FY26 net product revenue of $50.7 million, a 92% year-over-year increase, while the net loss widened to $230.4 million. Adjusted net loss narrowed to $81.0 million. R&D and SG&A expenses rose to $60.8 million and $51.8 million, respectively. The company holds $357.4 million in cash and securities, with an FDA PDUFA date set for January 6, 2027, for ANKTIVA's sBLA.
- ImmunityBio posted Q2 net product revenue of $50.7 million, up 92% year-over-year and up 15% sequentially. * Net loss attributable to common stockholders widened to $230.4 million; adjusted net loss (non-GAAP) narrowed to $81.0 million. * R&D expense rose to $60.8 million; SG&A expense increased to $51.8 million. * First-half net product revenue climbed to $94.8 million, up 121% versus the prior-year period. * Cash, cash equivalents and marketable securities totaled $357.4 million; FDA set a Jan. 6, 2027 PDUFA date for an ANKTIVA sBLA. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608040730BIZWIRE_USPR_____20260804_BW702957) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)